기사

[MD Today = Reporter Park Seong-ha]

Medisarang, a specialized manufacturer of PRP kits, has entered into a joint initiative for a new PRP business with Humedix, an aesthetics-focused company under the Huons Group. Beyond simple product supply, the two companies aim to establish a strategic partnership covering the entire value chain—from planning and development to marketing and distribution—securing a new growth engine in Korea’s regenerative aesthetics market.

Medisarang, responsible for product manufacturing, is a subsidiary of Prodizen, a developer of PRP kits and related medical devices. It operates GMP-certified production facilities and independently develops and manufactures PRP kits that separate high-concentration platelets rich in growth factors from patient blood. The company directly owns both production capabilities and intellectual property (IP), and its products—based on domestic medical device approvals and certifications—are recognized for their high reliability in terms of quality and safety.

Humedix, on the other hand, is an aesthetics specialist within the Huons Group, offering a broad portfolio including hyaluronic acid (HA) fillers, botulinum toxin, and skin boosters. Its nationwide distribution network, marketing capabilities, and strong medical professional network are expected to play a key role in accelerating market entry.

The two companies plan to collaborate across product planning, development, marketing, distribution, and sales. Through this, they aim to implement an integrated platform that functionally expands beyond conventional PRP procedures. In particular, Medisarang is currently developing an LED-based solution for PRP activation, focusing on securing differentiated technology compared to existing PRP products—raising expectations for strong synergy from this partnership. Product development and registration are underway, targeting mass production and an official launch in the second half of 2026.

CEO Sim Su-ja stated, “Based on our long-standing expertise in cell therapy technology, we aim to present a differentiated regenerative medicine solution that advances beyond the existing PRP market through this collaboration with Humedix.”

CEO Kang Min-jong added, “Medisarang’s PRP kit has already proven its competitiveness in the market based on its technical completeness. By incorporating activation solutions, we expect to evolve it into an expanded platform that goes beyond conventional PRP procedures. Through this agreement, we have secured a portfolio capable of creating synergy with our existing aesthetic product lineup, and we will actively accelerate market entry and business expansion through protocol development.”